TOURing for answers

Theravance Biopharma Inc. is launching an observational study to answer physician questions about real-world use of Vibativ telavancin that weren't explored in its registrational trials. The company hopes it will help prove the antibiotic's dual mechanism of action results in little propensity to cause resistance.

Such studies may become increasingly important as FDA seeks ways to streamline development pathways for antibiotics in ways that reduce the amount of data collected before approval...